Biomerica Inc (NASDAQ:BMRA) does about 1.00M shares in volume on a normal day but saw 5086074 shares change hands in the recent trading day. The company now has a market cap of 8.37M USD. Its current market price is $0.41, marking an increase of 5.73% compared to the previous close of $0.39. The 52 week high reached by this stock is $2.13 whilst the lowest price level in 52 weeks is $0.24.
Biomerica Inc (BMRA) has a 20-day trading average at $0.3511 and the current price is -80.67% off the 52-week high compared with 70.52% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.3375 and its 200-day simple moving average is $0.5463. If we look at the stock’s price movements over the week, volatility stands at 19.51%, which decreases to 11.65% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 66.07 to suggest the stock is neutral.
The consensus objective for the share price is $13.00, suggesting that the stock has a potential upside of 96.85% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 10, 2020 when Colliers Securities initiated the stock to “Buy” and issued a price target of $13.
The current price level is 17.29%, 22.02%, and -24.63% away from its SMA20, SMA50, and SMA200 respectively, with the BMRA price moving below the 50-day SMA on current market day. Biomerica Inc (BMRA) stock is up 31.15% over the week and 10.70% over the past month. Its price is -67.06% year-to-date and -55.72% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 96.85 percent from here.
Outstanding shares total 16.82M with insiders holding 7.21% of the shares and institutional holders owning 12.36% of the company’s common stock. The company has a return on investment of -107.75% and return on equity of -76.48%. The beta has a value of -1.11. Price to book ratio is 1.30 and price to sales ratio is 1.52.
